| Bid | 1.5 |
| Market Cap | 4.31M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -32.59 |
| PE Ratio (ttm) | -0.05 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 1.59 |
| Volume | 263,295 |
| Avg. Volume (20D) | 1,992,080 |
| Open | 1.62 |
| Previous Close | 1.91 |
| Day's Range | 1.50 - 1.64 |
| 52-Week Range | 1.14 - 17.00 |
| Beta | undefined |
About TOVX
Theriva Biologics Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and...
Analyst Forecast
According to 1 analyst ratings, the average rating for TOVX stock is "Buy." The 12-month stock price forecast is $6, which is an increase of 287.12% from the latest price.
9 months ago · seekingalpha.com
Theriva Biologics, Inc. (TOVX) Q4 2023 Earnings Call TranscriptTheriva Biologics, Inc. (TOVX) Q4 2023 Earnings Call Transcript
1 year ago · proactiveinvestors.com
Theriva Biologics jumps on US FDA approval for pancreatic cancer treatmentTheriva Biologics Inc saw its shares surge over 70% higher in after-hours US trading following news that its lead clinical candidate, VCN-01, has been granted orphan drug designation by the US Food an...
